Clinical Trial Update: Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II trial evaluating neratinib plus capmatinib in metastatic breast cancer and inflammatory breast cancer with abnormal HER-family and c-Met signaling…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer

Drugs mentioned

• Capmatinib (capmatinib)
• neratinib (neratinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Breast Cancer, Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-15